ReviewMaterials (Basel, Switzerland)2026
Polymeric Therapeutic Nanosystems Containing Paclitaxel: Novel Strategies, Therapeutic Potential, Challenges, and Translation Problems.
Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers still remain one of the most significant challenges in medicine or pharmacy, accounting for nearly 10 million deaths annually and imposing a substantial socioeconomic burden worldwide. Although chemotherapy continues to play a central role in the treatment of many tumors, conventional anticancer therapies are frequently associated with poor selectivity, systemic toxicity, multidrug resistance, and unfavorable pharmacokinetic profiles. Paclitaxel (PTX), one of the most widely used antineoplastic agents, demonstrates remarkable clinical efficacy against breast, ovarian, lung, pancreatic, and several other malignancies. Nevertheless, its clinical application remains limited by poor aqueous solubility, non-specific biodistribution, dose-limiting toxicities, and the development of resistance mechanisms. Nanotechnology-based anticancer drug delivery systems have emerged as a promising strategy to address these limitations. Among them, polymeric nanosystems have attracted particular attention owing to their physicochemical properties, biocompatibility, controlled drug-release capabilities, and potential for tumor-targeted delivery. Natural, semi-synthetic, and synthetic polymers are extensively investigated as carriers for PTX, leading to the development of nanoparticles, micelles, nanogels, nanofibers, dendritic systems, and hybrid nanoplatforms. Nanosystems demonstrate enhanced therapeutic efficacy, reduced systemic toxicity, prolonged circulation times, and improved tumor accumulation in preclinical models. Despite encouraging laboratory results, the clinical translation of polymeric PTX nanocarriers (NCs) remains limited. Numerous barriers, including tumor heterogeneity, variability of the enhanced permeability and retention (EPR) effect, manufacturing complexity, regulatory challenges, scale-up difficulties, and discrepancies between animal models and human cancers, continue to hinder successful commercialization and widespread clinical adoption. This review critically discusses the current state of polymeric drug delivery systems (DDSs) that contain PTX, as well as the advantages and limitations of synthetic, natural, and semi-synthetic polymers used in DDS technologies. Furthermore, translational challenges and future perspectives of PTX-based DDSs were analyzed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.